Vetoquinol® Phenylarthrite® 100ml

Vetoquinol® Phenylarthrite® 100ml

Phenylarthrite® Inject able solution 100ml

In dogs:
– Treatment of inflammation, pain and fever, especially during musculoskeletal disorders, congestive processes or inflammatory complications of traumatic or infectious conditions.

Pharmacodynamic properties

Phenylbutazone is a nonsteroidal anti-inflammatory drug of the pyrazole family which also has analgesic and antipyretic properties. It works by inhibiting the production of prostaglandins that are involved in the production of pain, inflammation and fever.

Its main metabolite, oxyphenbutazone, has similar pharmacological properties.

Pharmacokinetic characteristics

Phenylbutazone is a molecule with lipophilic properties; its solubility in water is low. Phenylbutazone is strongly bound to plasma proteins (> 98%). The plasma half-life increases with the dose. If administration is repeated, plasma residues accumulate.

Phenylbutazone is extensively metabolised by the liver before being eliminated. The major metabolites are oxyphenbutazone, γ-hydroxyphenylbutazone and γ-hydroxyoxyphenbutazone, accounting for 25-30% of the 24-hour dose.

Category:

Description

PHENYLARTHRITIS INJECTABLE

Drug interactions and other forms of interactions

Interactions are possible with the following substances:
– coumarin derivatives such as warfarin,
– penicillin G,
– furosemide and other diuretics,
– corticosteroids.Associations advised against:
– other NSAIDs (including salicylates in high doses): increased risk of ulcerative and digestive bleeding (additive synergy),
– heparin (parenteral): increased risk of bleeding,
– sulphonylureas hypoglycemic: increased hypoglycemic effect sulfonamides (displacement of their plasma protein binding and / or reduction of their elimination).Associations requiring precautions for use: 
– pentoxifylline: increased risk of haemorrhage.

Dosage and route of administration 
Route of administration: intramuscular deep and intravenous.

13.3 mg of phenylbutazone per kg of body weight per day, ie 1 ml of solution per 15 kg of body weight per day.

Intravenous injections should be performed slowly. During intravenous injections, avoid bubbling blood into the syringe.
Intramuscular injections should be performed deep in the muscle mass.

In any case, the injections should be administered with strict asepsis. If necessary, a second series of injections can be given one to two weeks later, in order to consolidate the therapeutic results. However, there is no need to increase the prescribed doses or to prolong the duration of treatment if no improvement occurs after 6 days.